Alimera Sciences Inc
NASDAQ:ALIM
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Alimera Sciences Inc
NASDAQ:ALIM
|
290.2m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
935.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.9B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
256.9B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
233.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.2B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
288.9B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
152.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Alimera Sciences Inc
Glance View
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. The company is headquartered in Alpharetta, Georgia and currently employs 145 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. The firm focuses on diseases affecting the retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. The Company’s product ILUVIEN is also used for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is also used in the European Economic Area (EEA) to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The firm commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Alimera Sciences Inc is 86.4%, which is above its 3-year median of 86%.
Over the last 3 years, Alimera Sciences Inc’s Gross Margin has decreased from 88.4% to 86.4%. During this period, it reached a low of 85.1% on Mar 31, 2023 and a high of 88.4% on Jun 30, 2021.
